At the CII Partnership Summit last December, Adar Poonawalla, CEO of Serum Institute of India (SII), said: "SII is working towards developing a vaccine booster shot which is more effective.
"We are in a continuous state of innovation and product development for Covaxin," says Krishna Ella, Chairman and MD of the Hyderabad-based company. The study, however, is yet to be peer reviewed.
Serum torrent russia series#
And Cadila Healthcare's vaccine Z圜ov-D has been approved for inoculating children (12-18 years) along with Covaxin (15-18 years).īharat Biotech recently announced results from a study conducted at Emory University, US, demonstrating that a booster dose of Covaxin six months after getting a primary two-dose series of the vaccine neutralises the Omicron and Delta variants. Other vaccine makers such as Novavax and Dynavax are pushing their vaccines as booster doses in India in collaboration with Indian companies. Reddy's Laboratories)-have already announced they are working on vaccines to beat the mutant variants of SARS CoV2, including Omicron. Manufacturers of the three major vaccines under the national Covid-19 immunisation programme-Covishield (from Serum Institute of India), Covaxin (Bharat Biotech) and Sputnik V (Dr. In the current crisis, growth will be driven by new vaccines and therapeutics to treat the highly infectious Omicron variant. That's a lot of money, considering the size of the Indian pharma market was $42 billion (more than Rs 3 lakh crore) in 2021, according to India's Economic Survey 2021. According to an analysis by Motilal Oswal, the share of Covid-19-related therapies stood at 44 per cent of the total Indian pharma market's sales at the peak of the second wave in April-May 2021. Aside from the tragedy of it all, this has also thrown open an opportunity for revenue growth for the Indian pharma industry. That much is clear from the electric pace of spread of the Omicron variant of the SARS CoV2 virus.
The covid-19 pandemic is not dying down anytime soon.
0 kommentar(er)
